It can be hypothesized that the anti-steatotic effect of leptin only applies in the early stages of MASLD, but if the disease progresses, leptin could exert proinflammatory and profibogenic actions [32,33]. The gene discussed is LEP; the disease is metabolic dysfunction-associated steatotic liver disease.